For this new addition to the GRACE Lung Cancer Video Library, Dr. Stephen Liu joins GRACE to discuss current updates in small cell lung cancer. In this video, Dr. Liu discusses updated information on immunotherapy for small cell lung cancer. To join the conversation, visit https://cancergrace.org

For this new addition to the GRACE Lung Cancer Video Library, Dr. Stephen Liu joins GRACE to discuss current updates in non small cell lung cancer. In this video, Dr. Liu discusses updated information on the leading treatment options for patients with negative tumor pd l1. To join the conversation

For this new addition to the GRACE Lung Cancer Video Library, Dr. Charu Aggarwal joins GRACE to discuss current updates in non small cell lung cancer. In this video, Dr. Aggarwal discusses updated information on the current status of tumor mutational burden, or TMB. To join the conversation, visit

For this new addition to the GRACE Lung Cancer Video Library, Dr. Charu Aggarwal joins GRACE to discuss current updates in non small cell lung cancer. In this video, Dr. Aggarwal discusses updated information on the utility of liquid biopsies. To join the conversation, visit https://cancergrace.org

For this new addition to the GRACE Lung Cancer Video Library, Dr. Taofeek Owonikoko joins GRACE to discuss current updates in small cell lung cancer. In this video, Dr. Owonikoko discusses updated information on treatment options for relapsed sclc. To join the conversation, visit https://cancergrace

Bronchioloalveolar carcinoma (BAC) is an unusual subtype of lung cancer; medical oncologist Dr. Jack West reviews the evidence on the best systemic therapy to treat advanced, multifocal BAC.

Dr. Jack West, Swedish Cancer Institute, compares the mechanism of action, efficacy and toxicity of PD-1 and PD-L1 inhibitors.

UCLA Med Center's Dr. Eddie Garon discusses the open question of the optimal duration of ongoing treatment with immunotherapy for lung cancer.

Dr. Eddie Garon considers the data on immunotherapies for first line treatment of advanced NSCLC and whether we are likely to use these agents instead of or in combination with standard chemotherapy soon.

Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, defines the V20 standard for lung radiation and outlines the advantages of limiting dose and field size in lung radiation therapy.

Stephen Liu, MD provides updates to our Lung Cancer Video Library. In this recent video, Dr. Liu discusses Continuing Immunotherapy Beyond Progression-In Which Patients Is This Appropriate

Dr. Jared Weiss, Vice President of GRACE and Associate Professor at UNC-Chapel Hill in Clinical Research, and the Thoracic Oncology Program at UNC Lineberger, discusses if there is a role for PD-L1 testing after first line treatment.

Dr. Luis Raez, MD FACP FCCP, Chief of Hematology/Oncology and Med. Director at Memorial Cancer Institute, and Clinical Associate Professor of Medicine at FL International University joined GRACE to discuss immune checkpoint inhibitors and how they can treat cancer.

Dr. Luis Raez, MD FACP FCCP, Chief of Hematology/Oncology and Medical Director at Memorial Cancer Institute, and Clinical Associate Professor of Medicine at Florida International University joined GRACE to discuss second-line therapies for advanced NSCLC.

Dr. Luis Raez, MD FACP FCCP, Chief of Hem/Onc and Med. Dir. at Memorial Cancer Institute, and Clinical Associate Prof. of Medicine at FL International U. joined GRACE to discuss integrating immune checkpoint inhibitors into first-line therapy for advanced NSCLC.